OncoMatch/Clinical Trials/NCT03326921
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Is NCT03326921 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR for juvenile myelomonocytic leukemia.
Treatment: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR — This phase I trial studies the side effects and best dose of CD4+ and CD8+ HA-1 T cell receptor (TCR) (HA-1 T TCR) T cells in treating patients with acute leukemia that persists, has come back (recurrent) or does not respond to treatment (refractory) following donor stem cell transplant. T cell receptor is a special protein on T cells that helps them recognize proteins on other cells including leukemia. HA-1 is a protein that is present on the surface of some peoples' blood cells, including leukemia. HA-1 T cell immunotherapy enables genes to be added to the donor cells to make them recognize HA-1 markers on leukemia cells.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Chronic Myeloid Leukemia
Myelodysplastic Syndrome
Biomarker criteria
Required: HLA-A A*0201 positive (A*0201 positive)
Subject must express HLA-A*0201
Required: HA-1 HA-1(H) genotype (RS_1801284: A/G, A/A) (A/G, A/A)
Subject must have the HA-1(H) genotype (RS_1801284: A/G, A/A)
Prior therapy
Must have received: allogeneic hematopoietic cell transplant
Subjects who are currently undergoing or who previously underwent allogeneic HCT
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Fred Hutch/University of Washington Cancer Consortium · Seattle, Washington
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify